ArticleInternational journal of cancer2020
Plasma metabolites associated with colorectal cancer stage: Findings from an international consortium.
Registry-linked trialOpen access · hybridAbstract read
In one paragraph
Article in International journal of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02328677 (ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis), which is not on this map. Cited by 37 papers.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis
Who cites it
37 citing papers in PubMed, 47 citations in OpenAlex.
- Plasma Metabolomics Analysis of Aspirin Treatment and Risk of Colorectal Adenomas.Cancer prevention research (Philadelphia, Pa.) · 2022Trial
- Unveiling the association between plasma lipid species and pan-cancers: A bidirectional 2-sample Mendelian randomization study.Medicine · 2026Article
- Review
- Multi-omics analysis reveals that FABP2 suppresses colorectal cancer progression by regulating sphingomyelin metabolism via the PPAR signaling pathway.Cancer cell international · 2026Article
- Crosstalk between mFrontiers in immunology · 2026Review
- Serum untargeted metabolomics analysis of colorectal cancer.BMC cancer · 2025Article
- Potentialities and challenges of liquid biopsy in clinical cancer management.Biomarkers in medicine · 2025Review
- Exploring causal associations between nuclear magnetic resonance biomarkers and colorectal cancer risk.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer.Molecular oncology · 2025Article
- Skincare Benefits of a Postbiotic Ferment Produced Through Djon Djon Mushroom Fermentation by Saccharomyces.Journal of cosmetic dermatology · 2025Article
- Genetically Predicted Immune Cell Traits Mediate the Causal Association Between Plasma Metabolites and Colorectal Cancer.Journal of Cancer · 2025Article
- Inflammation mediates the effect of histidine on a lower risk of colorectal cancer.Frontiers in nutrition · 2025Article
- The Potential of Metabolomics in Colorectal Cancer Prognosis.Metabolites · 2024Review
- Two Decades of Progress in Personalized Medicine of Colorectal Cancer in Serbia-Insights from the Institute for Oncology and Radiology of Serbia.Biomedicines · 2024Article
- Liquid Biopsy in the Clinical Management of Cancers.International journal of molecular sciences · 2024Review
- Changes in Faecal Microbiota Profile and Plasma Biomarkers following the Administration of an Antioxidant Oleuropein-Rich Leaf Extract in a Rat Model Mimicking Colorectal Cancer.Antioxidants (Basel, Switzerland) · 2024Article
- Biological and Clinical Characteristics of Proximal Colon Cancer: Far from Its Anatomical Subsite.International journal of medical sciences · 2024Review
- Metabolomic biomarkers in liquid biopsy: accurate cancer diagnosis and prognosis monitoring.Frontiers in oncology · 2024Review
- Review
- Profiling the metabolic disorder and detection of colorectal cancer based on targeted amino acids metabolomics.Journal of translational medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
44 authors at 15 institutions in 6 countries.
Anne J M R GeijsenDivision of Human Nutrition and Health, Wageningen University & Research, Wageningen, The Netherlands.ORCID 0000-0002-9272-7703
Eline H van RoekelDepartment of Epidemiology, GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.
Fränzel J B van DuijnhovenDivision of Human Nutrition and Health, Wageningen University & Research, Wageningen, The Netherlands.ORCID 0000-0001-8367-2352
David AchaintreBiomarkers Group, International Agency for Research on Cancer, Lyon, France.
Thomas Bachleitner-HofmannDepartment of Surgery, Medical University Vienna, Vienna, Austria.
Andreas BaierlDepartment of Statistics and Operations Research, University of Vienna, Vienna, Austria.
Michael M BergmannDepartment of Surgery, Medical University Vienna, Vienna, Austria.
Jürgen BoehmHuntsman Cancer Institute, Salt Lake City, UT.
Martijn J L BoursDepartment of Epidemiology, GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.
Hermann BrennerDivision of Preventive Oncology, National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany.
Stéphanie O BreukinkDepartment of Surgery, GROW School for Oncology and Development Biology, Maastricht University, Maastricht, The Netherlands.
Stefanie BrezinaInstitute of Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Jenny Chang-ClaudeDivision of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
Esther HerpelInstitute of Pathology, University of Heidelberg, Heidelberg, Germany.
Johannes H W de WiltDepartment of Surgery, Division of Surgical Oncology and Gastrointestinal Surgery, Radboud University Medical Center, Nijmegen, The Netherlands.
Audrey GicquiauBiomarkers Group, International Agency for Research on Cancer, Lyon, France.
Biljana GigicDepartment of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.
Tanja GumpenbergerInstitute of Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Bibi M E HanssonDepartment of Surgery, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.
Michael HoffmeisterDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Andreana N HolowatyjHuntsman Cancer Institute, Salt Lake City, UT.ORCID 0000-0001-8001-8793
Judith Karner-HanuschDepartment of Surgery, Medical University Vienna, Vienna, Austria.
Pekka Keski-RahkonenBiomarkers Group, International Agency for Research on Cancer, Lyon, France.
Eric T P KeulenDepartment of Internal Medicine and Gastroenterology, Zuyderland Medical Center, Sittard, The Netherlands.
Janna L KooleDepartment of Epidemiology, GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.ORCID 0000-0002-9927-9034
Gernot LeebHospital Oberpullendorf, Burgenland, Austria.
Jennifer OseHuntsman Cancer Institute, Salt Lake City, UT.ORCID 0000-0002-2030-9676
Peter SchirmacherInstitute of Pathology, University of Heidelberg, Heidelberg, Germany.
Martin A SchneiderDepartment of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.
Petra Schrotz-KingDivision of Preventive Oncology, National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany.
Anton StiftDepartment of Surgery, Medical University Vienna, Vienna, Austria.
Arve UlvikBEVITAL, Bergen, Norway.
F Jeroen VogelaarDepartment of Surgery, VieCuri Medical Center, Venlo, The Netherlands.
Evertine WesselinkDivision of Human Nutrition and Health, Wageningen University & Research, Wageningen, The Netherlands.
Moniek van ZutphenDivision of Human Nutrition and Health, Wageningen University & Research, Wageningen, The Netherlands.
Andrea GsurInstitute of Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-9795-1528
Nina HabermannDivision of Preventive Oncology, National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany.
Ellen KampmanDivision of Human Nutrition and Health, Wageningen University & Research, Wageningen, The Netherlands.
Augustin ScalbertBiomarkers Group, International Agency for Research on Cancer, Lyon, France.
Per M UelandBEVITAL, Bergen, Norway.
Alexis B UlrichDepartment of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.
Cornelia M UlrichHuntsman Cancer Institute, Salt Lake City, UT.ORCID 0000-0001-7641-059X
Matty P WeijenbergDepartment of Epidemiology, GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.
Dieuwertje E KokDivision of Human Nutrition and Health, Wageningen University & Research, Wageningen, The Netherlands.
Wageningen University & Research · NLGerman Cancer Research Center · DEHeidelberg University · DEMaastricht University · NLCentre international de recherche sur le cancer · FRMedical University of Vienna · ATUniversity of Utah · USComprehensive Cancer Center Vienna · ATBevital (Norway) · NOCanisius-Wilhelmina Ziekenhuis · NLRadboud University Nijmegen · NLUniversity of Applied Sciences Burgenland · ATUniversity of Vienna · ATVieCuri Medisch Centrum · NLZuyderland Medisch Centrum · NL
Funding
Transdisciplinary Team Science in Colorectal Cancer Prognosis: the ColoCare StudyU01CA206110 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jane C. Figueiredo, Christopher I Li · 2016 to 2026
$18.6MDiscovery and verification of novel biomarkers of colorectal cancer recurrenceR01CA189184 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LI, CHRISTOPHER I, ULRICH, CORNELIA M · 2015 to 2020
$5.6MMetabolomic Strategies for Discovery and Validation of Biomarkers of Colorectal Cancer RecurrenceR01CA207371 · NCI · UNIVERSITY OF UTAH · PI LI, CHRISTOPHER I, ULRICH, CORNELIA M · 2017 to 2022
$3.9MTraining Program in Genomic MedicineT32HG008962 · NHGRI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Lynn Jorde, Aaron R Quinlan · 2016 to 2026
$3.0MNCI NIH HHS R01 CA189184NCI NIH HHS R01 CA207371NCI NIH HHS U01 CA206110NHGRI NIH HHS T32 HG008962World Health Organization 001
Abstract
Colorectal cancer is the second most common cause of cancer-related death globally, with marked differences in prognosis by disease stage at diagnosis. We studied circulating metabolites in relation to disease stage to improve the understanding of metabolic pathways related to colorectal cancer progression. We investigated plasma concentrations of 130 metabolites among 744 Stages I-IV colorectal cancer patients from ongoing cohort studies. Plasma samples, collected at diagnosis, were analyzed with liquid chromatography-mass spectrometry using the Biocrates AbsoluteIDQ™ p180 kit. We assessed associations between metabolite concentrations and stage using multinomial and multivariable logistic regression models. Analyses were adjusted for potential confounders as well as multiple testing using false discovery rate (FDR) correction. Patients presented with 23, 28, 39 and 10% of Stages I-IV disease, respectively. Concentrations of sphingomyelin C26:0 were lower in Stage III patients compared to Stage I patients (p
Indexed as
AgedBiomarkers, TumorCitrullineColorectal NeoplasmsDisease ProgressionFemaleHistidineHumansLogistic ModelsMaleMetabolomicsMiddle AgedMulticenter Studies as TopicNeoplasm StagingObservational Studies as TopicProspective StudiesBiomarkers, TumorCitrullineHistidineSphingomyelinscolorectal cancerdisease stageepidemiologymetabolomicsplasma metabolites
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT02328677ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.